Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
Department of Microbiology, Haukeland University Hospital, Bergen, Norway.
Infect Dis (Lond). 2022 Feb;54(2):79-89. doi: 10.1080/23744235.2021.1974539. Epub 2021 Sep 16.
COVID-19 patients are extensively treated with antibiotics despite few bacterial complications. We aimed to study antibiotic use in hospitalized COVID-19 patients compared to influenza patients in two consecutive years. Furthermore, we investigated changes in antibiotic use from the first to second pandemic wave.
This prospective study included both patients from two referral hospitals in Bergen, Norway, admitted with influenza ( = 215) during the 2018/2019 epidemic and with COVID-19 ( = 82) during spring/summer 2020, and national data on registered Norwegian COVID-19 hospital admissions from March 2020 to January 2021 ( = 2300). Patient characteristics were compared, and logistic regression analysis was used to identify risk factors for antibiotic use.
National and local COVID-19 patients received significantly less antibiotics (53% and 49%) than influenza patients (69%, < .001). Early antibiotics contributed to >90% of antibiotic prescriptions in the two local hospitals, and >70% of prescriptions nationally. When adjusted for age, comorbidities, symptom duration, chest X-ray infiltrates and oxygen treatment, local COVID-19 patients still had significantly lower odds of antibiotic prescription than influenza patients (aOR 0.21, 95%CI 0.09-0.50). At the national level, we observed a significant reduction in antibiotic prescription rates in the second pandemic wave compared to the first (aOR 0.35, 95% CI 0.29-0.43).
Fewer COVID-19 patients received antibiotics compared to influenza patients admitted to the two local hospitals one year earlier. The antibiotic prescription rate was lower during the second pandemic wave, possibly due to increased clinical experience and published evidence refuting the efficacy of antibiotics in treating COVID-19 pneumonia.
尽管 COVID-19 患者很少有细菌并发症,但仍广泛使用抗生素进行治疗。我们旨在研究连续两年住院 COVID-19 患者与流感患者的抗生素使用情况。此外,我们还调查了从第一波大流行到第二波大流行期间抗生素使用的变化。
本前瞻性研究纳入了 2018/2019 年流感流行期间在挪威卑尔根的两家转诊医院住院的流感患者( = 215)和 2020 年春/夏季 COVID-19 患者( = 82),以及 2020 年 3 月至 2021 年 1 月期间挪威 COVID-19 住院患者的全国登记数据( = 2300)。比较了患者特征,并使用逻辑回归分析确定了抗生素使用的危险因素。
全国和地方 COVID-19 患者接受抗生素治疗的比例明显低于流感患者(分别为 53%和 49%, < .001)。在当地的两家医院,早期抗生素治疗贡献了超过 90%的抗生素处方,而全国范围内则超过 70%。在校正年龄、合并症、症状持续时间、胸部 X 线浸润和氧疗后,当地 COVID-19 患者接受抗生素治疗的可能性仍明显低于流感患者(调整后的优势比 0.21,95%CI 0.09-0.50)。在全国范围内,与第一波大流行相比,第二波大流行期间抗生素处方率显著下降(调整后的优势比 0.35,95%CI 0.29-0.43)。
与一年前在当地两家医院住院的流感患者相比,COVID-19 患者接受抗生素治疗的比例较低。第二波大流行期间,抗生素处方率较低,可能是由于临床经验增加,以及发表的证据反驳了抗生素治疗 COVID-19 肺炎的疗效。